Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.

AIMS To determine the incidence of hepatitis C virus (HCV) infection and identify risk factors for seroconversion. DESIGN Prospective cohort study. Participants were recruited through direct approaches, street-based outreach, methadone and sexual health clinics and needle and syringe programmes. SETTING Urban, regional and rural settings in New South Wales, Australia. PARTICIPANTS Injecting drug users (IDUs) (n = 584) were screened and tested for exposure to HCV. Between 1999 and 2002 antibody HCV negative IDUs (n = 368) were enrolled and followed-up every 3-6 months until seroconversion or study completion. MEASUREMENTS Interviewer-administered baseline and follow-up questionnaires consisted of 131 items and included demographics, drug use and risk behaviour. Approximately 10 cc of whole blood was drawn at each visit. Specimens were stored at -70C and serology performed using one or two third-generation enzyme-linked immunosorbent assays and polymerase chain reaction testing. FINDINGS Sixty-eight seroconversions were observed and incidence was 30.8 per 100 person-years, with incidence in IDUs injecting < 1 year, 133 per 100 person-years. Independent predictors of seroconversion were female gender, duration of injecting, injecting cocaine, shared use of filters and recruitment strategy. CONCLUSIONS Women, new initiates and IDUs recruited via outreach appear to be at increased risk of infection. Results confirm the significance of cocaine injection as a risk factor and provide the first evidence outside North America of the link between shared use of drug preparation equipment and incident HCV infection. Prevention efforts should attempt to raise awareness of the risks associated with drug sharing and, in particular, the role of potentially contaminated syringes in HCV infection.

[1]  P. Bourgois,et al.  The Everyday Violence of Hepatitis C Among Young Women Who Inject Drugs in San Francisco. , 2004, Human organization.

[2]  J. Pawlotsky Use and interpretation of virological tests for hepatitis C , 2002, Hepatology.

[3]  D. Vlahov,et al.  Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. , 1993, Addiction.

[4]  D. Vlahov,et al.  Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[5]  M. MacDonald,et al.  Risk factors for hepatitis C virus infection among injecting drug users in Sydney. , 1994, Genitourinary medicine.

[6]  J. Kaldor,et al.  Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995–1997 , 2000 .

[7]  P. Griffiths,et al.  Evaluation of a Brief Intervention to Prevent Initiation into Injecting , 1998 .

[8]  L. Maher,et al.  Risk behaviours of young Indo‐Chinese injecting drug users in Sydney and Melbourne , 2001, Australian and New Zealand journal of public health.

[9]  P. Bourgois,et al.  The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments. , 1998, Substance use & misuse.

[10]  M. Busch,et al.  Hepatitis C virus seroconversion among young injection drug users: relationships and risks. , 2002, The Journal of infectious diseases.

[11]  D. Harte,et al.  Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users. , 2000, The New Zealand medical journal.

[12]  B. Jalaludin,et al.  Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south‐western Sydney, Australia , 2004, Journal of gastroenterology and hepatology.

[13]  J. Parry,et al.  Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study , 2004, BMJ : British Medical Journal.

[14]  J. Goudsmit,et al.  Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. , 1990, The Journal of infectious diseases.

[15]  M. Schechter,et al.  Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic , 2003, AIDS.

[16]  D. D. Des Jarlais,et al.  Hepatitis C Virus Infection Among Injection Drug Users: Survival Analysis of Time to Seroconversion , 2004, Epidemiology.

[17]  L. Maher Sexed Work: Gender, Race, and Resistance in a Brooklyn Drug Market , 1997 .

[18]  J. Kaldor,et al.  Epidemiology of hepatitis C virus infection in Australia. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[19]  J. de Irala,et al.  Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. , 1996, American journal of epidemiology.

[20]  R. Garfein,et al.  Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. , 2002, American journal of epidemiology.

[21]  L. Maher Don't leave us this way: ethnography and injecting drug use in the age of AIDS , 2002 .

[22]  D. Vlahov,et al.  Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. , 2004, International journal of epidemiology.

[23]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[24]  C. Aitken,et al.  Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990‐1995 , 1997, The Medical journal of Australia.

[25]  D. Vlahov,et al.  Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland , 1997, Journal of clinical microbiology.

[26]  M. Schechter,et al.  Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection , 2022 .

[27]  M. Hickman,et al.  Measuring injecting risk behaviour in the second decade of harm reduction: a survey of injecting drug users in England. , 2000, Addiction.

[28]  M. Alter,et al.  Prevention of spread of hepatitis C , 2002, Hepatology.

[29]  Nick Crofts,et al.  Hepatitis C virus infection among a cohort of Victorian injecting drug users , 1993, The Medical journal of Australia.

[30]  M. MacDonald,et al.  Transmission of hepatitis C virus: rates, routes, and cofactors. , 1996, Epidemiologic reviews.

[31]  J. Montaner,et al.  Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users , 2002, Hepatology.

[32]  D. Vlahov,et al.  The natural history of hepatitis C virus infection: host, viral, and environmental factors. , 2000, JAMA.

[33]  J. Duchin,et al.  Sharing of drug preparation equipment as a risk factor for hepatitis C. , 2001, American journal of public health.

[34]  A. Widell,et al.  Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. , 2000, Scandinavian journal of infectious diseases.